Naoki Ishizuka

3.7k total citations
115 papers, 2.0k citations indexed

About

Naoki Ishizuka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Naoki Ishizuka has authored 115 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 36 papers in Surgery. Recurrent topics in Naoki Ishizuka's work include Gastric Cancer Management and Outcomes (38 papers), Lung Cancer Treatments and Mutations (14 papers) and Metastasis and carcinoma case studies (13 papers). Naoki Ishizuka is often cited by papers focused on Gastric Cancer Management and Outcomes (38 papers), Lung Cancer Treatments and Mutations (14 papers) and Metastasis and carcinoma case studies (13 papers). Naoki Ishizuka collaborates with scholars based in Japan, United States and United Kingdom. Naoki Ishizuka's co-authors include Tsutomu Yamazaki, Kazuyuki Shimada, Mitsuru Murata, Shinichiro Uchiyama, Katsuyuki Ando, Masahiro Sugawara, Kenji Yokoyama, Tamio Teramoto, Yasuo Ikeda and Shinichi Oikawa and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Naoki Ishizuka

105 papers receiving 2.0k citations

Peers

Countries citing papers authored by Naoki Ishizuka

Since Specialization

Citations

This map shows the geographic impact of Naoki Ishizuka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Ishizuka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Ishizuka more than expected).

Fields of papers citing papers by Naoki Ishizuka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Ishizuka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Ishizuka. The network helps show where Naoki Ishizuka may publish in the future.

Co-authorship network of co-authors of Naoki Ishizuka

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Ishizuka. A scholar is included among the top collaborators of Naoki Ishizuka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Ishizuka. Naoki Ishizuka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter prospective EN-MARK study: efficacy of third-line trastuzumab deruxtecan and dynamic changes in biomarkers, including HER2 status 2025 ·SHILAP Revista de lepidopterología ·Akira Ooki, (unknown), Kaoru Shimada, N. Machida, Hiroko Hara, (unknown), Naoki Ishizuka, Yoshiro Fukuda, Wataru Hashimoto, K Yamaguchi	0
2	A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Atsuo Takashima, (unknown), Kota Ouchi, Takeru Wakatsuki, Akira Ooki, Izuma Nakayama, Shota Fukuoka, (unknown), Daisuke Takahari, (unknown), Hidekazu Hirano, Hirokazu Shoji, (unknown), (unknown), Ken Kato, Naoki Ishizuka, Kensei Yamaguchi, (unknown)	1
3	1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab) 2023 ·Annals of Oncology ·(unknown), Daisuke Takahari, N. Yamamoto, Akira Ooki, Keisho Chìn, Naoko Kurihara, Tetsuo Mashima, Mariko Ogura, Izuma Nakayama, (unknown), Hidekazu Hirano, Keiko Minashi, Hiroki Hara, Ken Kato, Naoki Ishizuka, Sho Kitano, Hiroyuki Seimiya, Kengo Takeuchi, Narikazu Boku, Kensei Yamaguchi	1
4	Ultrasound evaluation of vagus nerve cross-sectional area in a community-dwelling elderly Japanese cohort 2023 ·PLoS ONE ·(unknown), Hiroshi Akasaka, Naoki Ishizuka, (unknown), Masahiro Kudo, Takashi Yamaguchi, (unknown), Ryo Itabashi, Tetsuya Maeda	2
5	Safety and efficacy of inside-stent as bridging therapy for malignant hilar biliary obstruction: single-centre prospective study 2022 ·British journal of surgery ·Yu Takahashi, Takashi Sasaki, Naoki Sasahira, Hiromichi Ito, Naoki Ishizuka, Yosuke Inoue, Yoshihiro Mise, Takafumi Sato, Yoshihiro Ono, Atsushi Oba, Akio Saiura	3
6	Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol 2022 ·BMJ Open ·Hiroki Osumi, Naoki Ishizuka, Atsuo Takashima, (unknown), Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, (unknown), Kota Ouchi, Takeru Wakatsuki, Narikazu Boku, Ken Kato, Kensei Yamaguchi, (unknown)	11
7	Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study 2022 ·Journal of Gastrointestinal Cancer ·(unknown), Takeru Wakatsuki, Daisuke Takahari, Tomohiro Matsushima, Naoki Ishizuka, Izuma Nakayama, Hiroki Osumi, Mariko Ogura, Takashi Ichimura, Eiji Shinozaki, Keisho Chìn, Kensei Yamaguchi	5
8	Postprandial Asymptomatic Glycemic Fluctuations after Gastrectomy for Gastric Cancer Using Continuous Glucose Monitoring Device 2021 ·Journal of the Korean Gastric Cancer Association ·Motonari Ri, Souya Nunobe, Satoshi Ida, Naoki Ishizuka, Shinichiro Atsumi, Masaru Hayami, Rie Makuuchi, Koshi Kumagai, Manabu Ohashi, Takeshi Sano	5
9	Usefulness of the l‐type Wako Helicobacter pylori antibody J test 2021 ·JGH Open ·Yoshitaka Tokai, Junko Fujisaki, Naoki Ishizuka, Hiroki Osumi, Ken Namikawa, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Kazumasa Miki, Tomohiro Tsuchida	6
10	Long-term high-grain diet alters ruminal pH, fermentation, and epithelial transcriptomes, leading to restored mitochondrial oxidative phosphorylation in Japanese Black cattle 2020 ·Scientific Reports ·(unknown), (unknown), Naoki Ishizuka, Eiji Iwamoto, (unknown), Keiichiro Kizaki, Yo‐Han Kim, Shigeru Sato	11
11	Performance of a computer-aided diagnosis system in diagnosing early gastric cancer using magnifying endoscopy videos with narrow-band imaging (with videos) 2020 ·Gastrointestinal Endoscopy ·Yusuke Horiuchi, Toshiaki Hirasawa, Naoki Ishizuka, Yoshitaka Tokai, Ken Namikawa, Shoichi Yoshimizu, Akiyoshi Ishiyama, Toshiyuki Yoshio, Tomohiro Tsuchida, Junko Fujisaki, Tomohiro Tada	59
12	Long-term high-grain diet altered the ruminal pH, fermentation, and composition and functions of the rumen bacterial community, leading to enhanced lactic acid production in Japanese Black beef cattle during fattening 2019 ·PLoS ONE ·(unknown), (unknown), Naoki Ishizuka, Eiji Iwamoto, (unknown), Kentaro Ikuta, Yo‐Han Kim, Shigeru Sato	31
13	Study on Clinical Factors Involved in <b><i>Helicobacter pylori</i></b>-Uninfected, Undifferentiated-Type Early Gastric Cancer 2017 ·Digestion ·Yusuke Horiuchi, Junko Fujisaki, Naoki Ishizuka, Masami Omae, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Yorimasa Yamamoto, Masatsugu Nagahama, Hiroshi Takahashi, Tomohiro Tsuchida	15
14	Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer 2016 ·Annals of Oncology ·Kokoro Kobayashi, (unknown), (unknown), Ippei Fukada, Naoki Ishizuka, Rie Horii, Shunji Takahashi, Futoshi Akiyama, Takuji Iwase, Shinji Ohno	2
15	Effects of Daily Aspirin on Cancer Incidence and Mortality in the Japanese 2015 ·Blood ·Kenji Yokoyama, Naoki Ishizuka, Naomi Uemura, Yuji Mizokami, Hideyuki Hiraishi, Tamio Teramoto, Kazuyuki Shimada, Yasuo Ikeda	1
16	Effects of telephone-delivered lifestyle support on the development of diabetes in participants at high risk of type 2 diabetes: J-DOIT1, a pragmatic cluster randomised trial 2015 ·BMJ Open ·Naoki Sakane, Kazuhiko Kotani, Kaoru Takahashi, Yoshiko Sano, Kokoro Tsuzaki, K. Okazaki, Juichi Sato, Sadao Suzuki, Satoshi Morita, Yoshitake Oshima, Kazuo Izumi, Masayuki Kato, Naoki Ishizuka, Mitsuhiko Noda, Hideshi Kuzuya	35
17	Phase II Trial of Neoadjuvant Chemotherapy with XELOX plus Bevacizumab for Locally Advanced Rectal Cancer 2011 ·Japanese Journal of Clinical Oncology ·Keisuke Uehara, Seiji Ishiguro, Eiji Sakamoto, Atsuyuki Maeda, M. Inoue, Y. Tojima, Satoshi Kobayashi, (unknown), Naoki Ishizuka, Akimasa Nakao, Hidemi Goto, Masato Nagino	13
18	Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events 2010 ·American Heart Journal ·Tamio Teramoto, Kazuyuki Shimada, Shinichiro Uchiyama, Masahiro Sugawara, Yoshio Gotō, Nobuhiro Yamada, Shinichi Oikawa, Katsuyuki Ando, Naoki Ishizuka, Tsutomu Yamazaki, Kenji Yokoyama, Mitsuru Murata, Yasuo Ikeda	18
19	A randomized controlled multicenter trial of post-suicide attempt case management for the prevention of further attempts in Japan (ACTION-J) 2009 ·BMC Public Health ·Yoshio Hirayasu, Chiaki Kawanishi, Naohiro Yonemoto, Naoki Ishizuka, Yoshiro Okubo, Akio Sakai, Taishiro Kishimoto, Hitoshi Miyaoka, Kotaro Otsuka, Yoshito Kamijo, Yutaka Matsuoka, Toru Aruga	25
20	Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A) 2003 ·Cancer Science ·Yuichiro Ohe, Naoki Ishizuka, Tomohide Tamura, Ikuo Sekine, Yutaka Nishiwaki, Nagahiro Saijo	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact